Filings & corporate actions
- 16 NovresultsResults · Q2 FY27 · standalone-0.8%NSE
- 29 OctresultsResults · Q2 FY27 · consolidated and standalone-7.0%NSE
- 16 OctshareholdingShareholding · 30 Sept 2026+4.7%NSE
- 27 JulresultsResults · Q1 FY27 · consolidated and standalone-6.2%NSE
- 20 JulshareholdingShareholding · 30 Jun 2026-1.4%NSE
- 27 MayresultsResults · Q4 FY26 · consolidated+0.7%NSE
- 14 MayresultsResults · Q4 FY26 · consolidated and standalone+10.0%NSE
- 7 AprshareholdingShareholding · 31 Mar 2026-0.8%NSE
- 20 JanresultsResults · Q3 FY26 · consolidated and standalone+6.4%NSE
- 12 JanshareholdingShareholding · 31 Dec 2025+0.3%NSE
Reaction to results · all yearsrose on day 0 in 5 of 8 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q2 FY27 | 29 Oct 2026 | -7.0% | -4.8% | — | 8.8× |
| Q1 FY27 | 27 Jul 2026 | -6.2% | -3.6% | +4.8% | 4.1× |
| Q4 FY26 | 14 May 2026 | +10.0% | +16.4% | +34.4% | 3.6× |
| Q3 FY26 | 20 Jan 2026 | +6.4% | -0.7% | +4.8% | 3.3× |
| Q2 FY26 | 6 Nov 2025 | +2.2% | -3.0% | -3.5% | 2.6× |
| Q1 FY26 | 24 Jul 2025 | -1.5% | -2.0% | +5.7% | 2.2× |
| Q4 FY25 | 19 May 2025 | +3.5% | +1.7% | +12.3% | 1.2× |
| Q3 FY25 | 24 Jan 2025 | +3.4% | +1.4% | -1.5% | — |
| Average | +1.4% | +0.7% | +8.2% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q2 FY27
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
Delivery percentage
Over the last 20 sessions SENORES settled 43.9% of its traded quantity, which is ordinary for an NSE equity. That is in line with its own one-year average of 45.7%. The latest session ranks higher than 86% of the 471 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
Dividends, deals & holders
Performance returns
| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -1.99% | -7.13% | -9.30% | -27.92% | -1.67% | +39.77% |
Valuation
Ownership
Quarterly results · consolidated
| Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 174.6 | 175.2 | 180.2 | 192.3 |
| YoY chg | +69.4% | +53.4% | +30.6% | +18.9% |
| Net profit (₹ Cr) | 33.6 | 36.7 | 30.5 | 36.6 |
| YoY chg | +104.4% | +104.1% | +43.8% | +21.5% |
| Net margin | 19.2% | 20.9% | 16.9% | 19.0% |
| EPS | 7.29 | 7.96 | 6.60 | 8.82 |
Shareholding over time
By quarter
30 Sept 2026 · promoter 45.82% · public 54.18%- Promoter
- Public and others
- Promoter
- 45.82%
- Public
- 54.18%
- Promoter change
- 0.00 pp
- Filed
- 16 Oct 2026
- FII
- 6.01%
- DII
- 10.84%
- Promoter pledged
- 2.81%
Who the public is
- Mutual funds
- 7.36%
- Insurance
- 1.28%
- FPI
- 6.01%
- Retail ≤ ₹2L
- 16.21%
- HNI > ₹2L
- 13.18%
- NRI
- 0.81%
- Bodies corporate
- 4.52%
- Shareholders
- 42,642
+0.80 pp QoQ
-0.34 pp QoQ
-0.61 pp QoQ
+0.74 pp QoQ
-0.59 pp QoQ
-0.07 pp QoQ
+0.37 pp QoQ
+16.8% QoQ
Major holders
As of 30 Sept 2026| Holder | Type | Holding | Shares |
|---|---|---|---|
| Swapnil Jatin Shah | Promoter · Individual | 7.72% | 35.54L |
| Ashokbhai Vijaysinh Barot | Promoter · Individual | 7.55% | 34.75L |
| Remus Pharmaceuticals Limited | Promoter · Corporate | 7.08% | 32.62L |
| Renosen Pharmaceuticals Private Limited | Promoter · Corporate | 5.90% | 27.19L |
| Anar Swapnil Shah | Promoter · Individual | 4.98% | 22.95L |
| Aviraj Overseas LLC | Promoter · Corporate | 4.12% | 18.95L |
| HSBC MUTUAL FUND - HSBC MULTI CAP FUND | Mutual fund | 2.87% | 13.20L |
| Sangeeta Mukur Barot | Promoter · Individual | 2.26% | 10.43L |
| MANOJ PRAKASH SANGHVI | Individual | 1.86% | 8.54L |
| RATNAMANI MARKETING PRIVATE LIMITED | Corporate | 1.82% | 8.38L |
Every promoter-group member, and each public holder above 1%, as filed.
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.
52-week highs & lows
Each session the stock traded past its previous 52-week high or low, from NSE's daily report; the previous figure is the record it broke. Prices as published, not split-adjusted.
Insider trades
- Insiders net, 30d
- ₹0
- Insiders net, 90d
- ₹0
- Promoters net, 90d
- ₹0
- Insider buyers, 90d
- 0
- Last promoter buy
- 11 months ago
- Disclosures on record
- 83
| Broadcast | Person | Side | Shares | Value | Price | Holding before → after | Stake | Regulation |
|---|---|---|---|---|---|---|---|---|
| 2 Mar 2026 | Dhruvalben Vishal ShahOther | Buy | 350 | ₹2.7L | 777.95 | 650 → 1.0K | 0.00%0.00 pp | 7(2)told 26 Feb 2026 |
| 1 Jan 2026 | Renosen Pharmaceuticals Private LimitedPromoter | Buy | 6.0K | ₹49.4L | 822.68 | 27.13L → 27.19L | 5.90%+0.01 pp | 7(2)told 1 Jan 2026 |
| 18 Dec 2025 | Renosen Pharmaceuticals Private LimitedPromoter | Buy | 4.0K | ₹32.2L | 803.92 | 27.09L → 27.13L | 5.89%+0.01 pp | 7(2)told 18 Dec 2025 |
| 16 Dec 2025 | Dhruvalben Vishal ShahOther | Buy | 150 | ₹1.1L | 761.50 | 400 → 550 | 0.00%0.00 pp | 7(2)told 15 Dec 2025 |
| 12 Dec 2025 | Vinodkumar Gandalal ShahOther | Buy | 300 | ₹2.3L | 782.96 | 1.4K → 1.6K | 0.00%0.00 pp | 7(2)told 12 Dec 2025 |
| 12 Dec 2025 | Vinodkumar Gandalal ShahOther | Buy | 100 | ₹78,314 | 783.14 | 1.3K → 1.4K | 0.00%0.00 pp | 7(2)told 12 Dec 2025 |
| 18 Nov 2025 | Pratik Sureshkumar ThakkarEmployee | Buy | 200 | ₹1.6L | 781.87 | 3.3K → 3.5K | 0.01%+0.00 pp | 7(2)told 17 Nov 2025 |
| 15 Sept 2025 | Pratik Sureshkumar Thakkar HUFOther | Buy | 350 | ₹2.4L | 688.26 | 400 → 750 | 0.00%0.00 pp | 7(2)told 13 Sept 2025 |
| 12 Sept 2025 | Chetan Bipinchandra ShahDirector | Buy | 500 | ₹3.6L | 713.49 | 4.0K → 4.5K | 0.01%+0.00 pp | 7(2)told 12 Sept 2025 |
| 29 Aug 2025 | Ashokbhai Vijaysinh BarotPromoter | Buy | 1.0K | ₹7.1L | 708.18 | 34.44L → 34.45L | 7.48%+0.00 pp | 7(2)told 29 Aug 2025 |
| 28 Aug 2025 | Renosen Pharmaceuticals Private LimitedPromoter | Buy | 2.5K | ₹17.5L | 698.13 | 27.06L → 27.09L | 5.88%+0.01 pp | 7(2)told 28 Aug 2025 |
| 22 Aug 2025 | Ashokbhai Vijaysinh BarotPromoter | Buy | 16.1K | ₹1.2Cr | 729.25 | 34.28L → 34.44L | 7.48%+0.03 pp | 7(2)told 22 Aug 2025 |
| 22 Aug 2025 | Renosen Pharmaceuticals Private LimitedPromoter | Buy | 1.0K | ₹7.0L | 698.90 | 27.05L → 27.06L | 5.88%+0.00 pp | 7(2)told 22 Aug 2025 |
| 22 Aug 2025 | Dhananjay Ashokkumar BarotPromoter | Sell | 5.1K | ₹36.0L | 704.00 | 3.18L → 3.13L | 0.68%-0.01 pp | 7(2)told 22 Aug 2025 |
| 22 Aug 2025 | Dhananjay Ashokkumar BarotPromoter | Sell | 7.1K | ₹49.8L | 701.00 | 3.25L → 3.18L | 0.69%-0.02 pp | 7(2)told 22 Aug 2025 |
| 22 Aug 2025 | Dhananjay Ashokkumar BarotPromoter | Sell | 5.1K | ₹35.2L | 690.00 | 3.30L → 3.25L | 0.71%-0.01 pp | 7(2)told 22 Aug 2025 |
| 1 Aug 2025 | Amee Chetan ShahRelative | Buy | 300 | ₹2.0L | 654.03 | 200 → 500 | 0.00%0.00 pp | 7(2)told 31 Jul 2025 |
| 29 Jul 2025 | Renosen Pharmaceuticals Private LimitedPromoter | Buy | 3.0K | ₹19.4L | 645.16 | 27.02L → 27.05L | 5.87%+0.01 pp | 7(2)told 28 Jul 2025 |
| 29 Jul 2025 | Chetan Bipinchandra ShahDirector | Buy | 500 | ₹3.3L | 663.04 | 3.5K → 4.0K | 0.01%+0.00 pp | 7(2)told 29 Jul 2025 |
| 28 May 2025 | Renosen Pharmaceuticals Private LimitedPromoter | Buy | 4.0K | ₹20.2L | 505.00 | 26.98L → 27.02L | 5.87%+0.01 pp | 7(2)told 28 May 2025 |
| 13 Mar 2025 | Chetan Bipinchandra ShahDirector | Buy | 550 | ₹3.1L | 564.39 | 3.0K → 3.5K | 0.01%+0.00 pp | 7(2)told 13 Mar 2025 |
| 27 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 1.0K | ₹5.6L | 561.83 | 2.0K → 3.0K | 0.00%0.00 pp | 7(2)told 27 Feb 2025 |
| 27 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 1.0K | ₹5.5L | 552.36 | 1.0K → 2.0K | 0.00%0.00 pp | 7(2)told 27 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 16 | ₹8,359 | 522.44 | 984 → 1.0K | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 142 | ₹74,181 | 522.40 | 842 → 984 | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 23 | ₹12,014 | 522.35 | 819 → 842 | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 46 | ₹24,025 | 522.28 | 773 → 819 | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 76 | ₹39,691 | 522.25 | 697 → 773 | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 37 | ₹19,321 | 522.19 | 660 → 697 | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 95 | ₹49,604 | 522.15 | 565 → 660 | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 23 | ₹12,008 | 522.09 | 542 → 565 | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 20 | ₹10,441 | 522.05 | 522 → 542 | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 298 | ₹1.6L | 521.95 | 224 → 522 | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 10 | ₹5,218 | 521.80 | 214 → 224 | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 29 | ₹15,132 | 521.79 | 185 → 214 | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 1 | ₹521 | 521.00 | 184 → 185 | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 21 Feb 2025 | Chetan Bipinchandra ShahDirector | Buy | 34 | ₹17,736 | 521.65 | 150 → 184 | 0.00%0.00 pp | 7(2)told 21 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 82 | ₹43,378 | 529.00 | 1.9K → 2.0K | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 61 | ₹32,253 | 528.74 | 1.9K → 1.9K | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 27 | ₹14,277 | 528.78 | 1.8K → 1.9K | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 4 | ₹2,115 | 528.75 | 1.8K → 1.8K | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 63 | ₹33,320 | 528.89 | 1.8K → 1.8K | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 289 | ₹1.5L | 528.95 | 1.5K → 1.8K | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 922 | ₹4.9L | 529.00 | 552 → 1.5K | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 1 | ₹528 | 528.00 | 551 → 552 | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 124 | ₹65,596 | 529.00 | 427 → 551 | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 4 | ₹2,109 | 527.25 | 423 → 427 | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 270 | ₹1.4L | 527.50 | 153 → 423 | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 30 | ₹15,823 | 527.43 | 123 → 153 | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 73 | ₹38,500 | 527.40 | 50 → 123 | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 18 | ₹9,492 | 527.33 | 32 → 50 | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 16 | ₹8,437 | 527.31 | 16 → 32 | 0.00%0.00 pp | 7(2)told 14 Feb 2025 |
| 17 Feb 2025 | Jeshika Hiten ParikhOther | Buy | 16 | ₹8,440 | 527.50 | — → 16 | 0.00% | 7(2)told 14 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 130 | ₹71,825 | 552.50 | 2.9K → 3.0K | 0.01%+0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 149 | ₹82,233 | 551.90 | 2.7K → 2.9K | 0.01%+0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 368 | ₹2.0L | 551.95 | 2.4K → 2.7K | 0.01%+0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 23 | ₹12,696 | 552.00 | 2.3K → 2.4K | 0.01%+0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 45 | ₹24,842 | 552.04 | 2.3K → 2.3K | 0.01%+0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 61 | ₹33,681 | 552.15 | 2.2K → 2.3K | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 65 | ₹35,893 | 552.20 | 2.2K → 2.2K | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 82 | ₹45,284 | 552.24 | 2.1K → 2.2K | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 180 | ₹99,414 | 552.30 | 1.9K → 2.1K | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 38 | ₹20,989 | 552.34 | 1.9K → 1.9K | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 10 | ₹5,524 | 552.40 | 1.8K → 1.9K | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 398 | ₹2.2L | 552.45 | 1.5K → 1.8K | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 317 | ₹1.8L | 552.50 | 1.1K → 1.5K | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 1 | ₹551 | 551.00 | 1.1K → 1.1K | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 454 | ₹2.5L | 552.50 | 679 → 1.1K | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 3 | ₹1,628 | 542.67 | 676 → 679 | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 1 | ₹542 | 542.00 | 675 → 676 | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 18 | ₹9,770 | 542.78 | 657 → 675 | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 527 | ₹2.9L | 543.00 | 130 → 657 | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 32 | ₹17,372 | 542.88 | 40 → 72 | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 38 | ₹20,628 | 542.84 | 2 → 40 | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 1 | ₹542 | 542.00 | 1 → 2 | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 1 | ₹542 | 542.00 | — → 1 | 0.00% | 7(2)told 13 Feb 2025 |
| 14 Feb 2025 | Sanjay Shaileshbhai MajmudarDirector | Buy | 58 | ₹31,491 | 542.95 | 72 → 130 | 0.00%0.00 pp | 7(2)told 13 Feb 2025 |
| 28 Jan 2025 | Renosen Pharmaceuticals Private LimitedPromoter | Buy | 4.0K | ₹20.2L | 504.44 | 26.94L → 26.98L | 5.86%+0.01 pp | 7(2)told 28 Jan 2025 |
SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.
How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session
Filings
CSVBulk & block deals · 24 Dec 2025
CSV| Date | Deal | Client | Quantity | Price | Value |
|---|---|---|---|---|---|
| 24 Dec 2025 | Sell · bulk | ASTORNE CAPITAL VCC ARVEN | 5.00L | 792.12 | ₹39.6Cr |
| 29 Jul 2025 | Sell · bulk | GRAVITON RESEARCH CAPITAL LLP | 3.16L | 689.98 | ₹21.8Cr |
| 29 Jul 2025 | Buy · bulk | GRAVITON RESEARCH CAPITAL LLP | 3.16L | 689.33 | ₹21.8Cr |
| 29 Jul 2025 | Buy · bulk | HRTI PRIVATE LIMITED | 2.69L | 686.66 | ₹18.5Cr |
| 29 Jul 2025 | Sell · bulk | HRTI PRIVATE LIMITED | 2.37L | 688.87 | ₹16.3Cr |
| 24 Jul 2025 | Sell · bulk | GRAVITON RESEARCH CAPITAL LLP | 6.39L | 685.44 | ₹43.8Cr |
| 24 Jul 2025 | Buy · bulk | GRAVITON RESEARCH CAPITAL LLP | 6.39L | 684.96 | ₹43.8Cr |
| 24 Jul 2025 | Sell · bulk | QE SECURITIES LLP | 2.48L | 684.18 | ₹17.0Cr |
| 24 Jul 2025 | Buy · bulk | QE SECURITIES LLP | 2.44L | 686.01 | ₹16.8Cr |
| 19 Mar 2025 | Buy · bulk | GRAVITON RESEARCH CAPITAL LLP | 2.38L | 635.98 | ₹15.1Cr |
| 19 Mar 2025 | Sell · bulk | GRAVITON RESEARCH CAPITAL LLP | 2.38L | 634.95 | ₹15.1Cr |
| 6 Feb 2025 | Sell · bulk | GRAVITON RESEARCH CAPITAL LLP | 3.12L | 609.00 | ₹19.0Cr |
A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.
Takeover-code disclosures
Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.
Every stock on this session →Short selling, lending & margin
Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.
Exchange surveillance
No surveillance measure applies to SENORES.
Price band: 20% · not in the F&O ban.
From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures.
Every stock on this session →Financials · quarterly statement
| Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Q2 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 103.0 | 114.2 | 138.0 | 161.8 | 174.6 | 175.2 | 180.2 | 192.3 | |
| Other income | 5.2 | 11.8 | 3.4 | 5.4 | 3.8 | 17.7 | 2.8 | 8.9 | |
| Total income | 108.2 | 126.0 | 141.4 | 167.2 | 178.3 | 192.9 | 183.0 | 201.3 | |
| Total expenses | 87.7 | 105.3 | 114.9 | 126.5 | 133.7 | 145.5 | 143.6 | 153.7 | |
| └ Finance costs | 6.2 | 5.3 | 5.0 | 6.2 | 5.3 | 8.5 | 7.2 | 8.8 | |
| └ Depreciation | 4.2 | 5.2 | 6.0 | 8.1 | 7.9 | 9.3 | 9.9 | 10.3 | |
| Profit before tax | 20.5 | 20.7 | 26.5 | 40.6 | 44.6 | 47.4 | 39.5 | 47.6 | |
| Tax expense | 4.1 | 2.7 | 5.3 | 10.5 | 11.0 | 10.7 | 9.0 | 11.0 | |
| Net profit | 16.4 | 18.0 | 21.2 | 30.1 | 33.6 | 36.7 | 30.5 | 36.6 | |
| EPS | 5.04 | 3.81 | 4.60 | 6.54 | 7.29 | 7.96 | 6.61 | 8.85 | |
| Net margin | 15.95% | 15.73% | 15.35% | 18.62% | 19.24% | 20.93% | 16.90% | 19.03% | |
| PBT margin | 19.88% | 18.11% | 19.20% | 25.12% | 25.55% | 27.06% | 21.90% | 24.74% | |
| Tax rate | 19.79% | 13.10% | 20.05% | 25.89% | 24.71% | 22.64% | 22.83% | 23.08% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 29 Oct 2026.
Balance sheet & cash flow · half-yearly
Balance sheet
| FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|
| Total assets | 1,226.9 | 1,288.2 | 1,603.8 | 1,680.6 | |
| Current assets | 722.4 | 663.8 | 812.4 | 766.3 | |
| └ Cash & equivalents | 105.4 | 86.0 | 45.6 | 18.0 | |
| └ Other bank balances | 280.1 | 116.6 | 114.1 | 82.7 | |
| └ Current investments | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Trade receivables | 123.9 | 199.5 | 324.8 | 253.2 | |
| └ Inventories | 56.6 | 62.6 | 89.3 | 97.6 | |
| Total equity | 812.2 | 834.4 | 964.5 | 1,031.5 | |
| └ Attributable to owners | 786.2 | 814.0 | 933.6 | 1,003.0 | |
| └ Non-controlling interest | 26.1 | 20.4 | 30.9 | 28.6 | |
| └ Share capital | 46.1 | 46.1 | 46.1 | 46.1 | |
| Borrowings | 304.8 | 231.8 | 327.1 | 394.5 | |
| └ Current | 142.3 | 79.1 | 132.2 | 181.6 | |
| └ Non-current | 162.5 | 152.7 | 194.9 | 212.9 | |
| Trade payables | 67.2 | 123.8 | 234.7 | 151.1 | |
| Current liabilities | 240.7 | 277.7 | 424.0 | 411.6 | |
| Total liabilities | 414.6 | 453.7 | 639.3 | 649.1 | |
| Net debt | (80.7) | 29.2 | 167.5 | 293.8 | |
| Debt / equity | 0.38 | 0.28 | 0.34 | 0.38 | |
| Current ratio | 3.00 | 2.39 | 1.92 | 1.86 |
Cash flow, year to date
| FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|
| Operating cash flow | (45.9) | 24.2 | 62.1 | 29.2 | |
| └ Capex | (157.5) | (96.7) | (240.1) | (136.6) | |
| Free cash flow | (203.4) | (72.5) | (178.1) | (107.4) | |
| Investing cash flow | (429.5) | 41.3 | (120.6) | (112.2) | |
| Financing cash flow | 573.1 | (84.9) | (1.3) | 55.4 | |
| └ Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Buybacks | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net change in cash | 97.7 | (19.4) | (59.8) | (27.6) |
From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.
Announcements & board meetings
As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.
Every stock on this session →SENORES at a glance
- SENORES closed at ₹1,090.8 on 20 Nov 2026, -1.99% on the day, +39.8% over one year, 31.8% below its 52-week high of ₹1,599.
- Delivery was 52.6% of traded quantity on 20 Nov 2026, the 86th percentile of its own 471 sessions with a reading (20-session average 43.9%, 1-year average 45.7%).
- Market capitalisation is ₹5,024 crore at a trailing P/E of 36.3 (trailing EPS ₹30.08).
- Q2 FY27 results (consolidated, filed 29 Oct 2026): revenue ₹192 crore (+18.9% year on year), net profit ₹37 crore (+21.5%); the price moved -7.0% on the first session after.
- Promoters held 45.82% at 30 Sept 2026, unchanged on the previous filing, with 2.81% of promoter shares pledged.
- Q3 FY27 results are expected between 20 Jan 2027 and 18 Feb 2027, going by past filing dates — an estimate, not an announcement.
About
Sector history
- to 5 Oct 2026Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
- from 5 Oct 2026Index industry · Healthcare
NSE’s own classification, by the snapshot it changed on.
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.
More in Pharmaceuticals & Biotechnology
- DIDIVISLABDivi's Laboratories Limited11,180.50+0.02%
- LALAURUSLABSLaurus Labs Limited2,294.60-0.49%
- SUSUNPHARMASun Pharmaceutical Industries Limited1,884.90-0.79%
- ACACUTAASAcutaas Chemicals Limited3,833.50-3.61%
- SASAILIFESai Life Sciences Limited1,800.70+0.69%
- PPPPLPHARMAPiramal Pharma Limited239.30-0.15%
- DRDRREDDYDr. Reddy's Laboratories Limited1,390.20-0.76%
- GLGLENMARKGlenmark Pharmaceuticals Limited2,648.00+1.51%
- AUAUROPHARMAAurobindo Pharma Limited1,799.00-0.37%
- CICIPLACipla Limited1,415.00-0.25%
- ZYZYDUSLIFEZydus Lifesciences Limited1,200.00-0.24%
- MAMANKINDMankind Pharma Limited2,665.00+1.37%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE